TIMP-2

Summary

Gene Symbol: TIMP-2
Description: TIMP metallopeptidase inhibitor 2
Alias: CSC-21K, DDC8, metalloproteinase inhibitor 2, testicular secretory protein Li 57, tissue inhibitor of metalloproteinases 2
Species: human

Top Publications

  1. ncbi mRNA expressions of TIMP-1, -2, and -3 and 92-KD type IV collagenase in early human placenta and decidual membrane as studied by in situ hybridization
    T Hurskainen
    Department of Pathology, University of Oulu, Finland
    J Histochem Cytochem 44:1379-88. 1996
  2. pmc Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor
    E Toschi
    Laboratory of Virology, Istituto Superiore di Sanita, 00161 Rome, Italy
    Mol Biol Cell 12:2934-46. 2001
  3. ncbi E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A)
    Linda Troeberg
    Kennedy Institute of Rheumatology Division, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, Hammersmith, London, W6 8LH UK
    Biochemistry 41:15025-35. 2002
  4. ncbi TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism
    Dong Wan Seo
    National Cancer Institute, Center for Cancer Research, Vascular Biology Faculty and Laboratory of Pathology, Extracellular Matrix Pathology Section, National Institutes of Health, Bethesda, MD 20892, USA
    Cell 114:171-80. 2003
  5. ncbi Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes
    Yifeng Zhou
    Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Carcinogenesis 25:399-404. 2004
  6. ncbi Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart
    Stephane Heymans
    CARIM, University Hospital Maastricht, Maastricht, The Netherlands
    Circulation 112:1136-44. 2005
  7. ncbi Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP)
    S Zucker
    Department of Medicine, Department of Veterans Affairs Medical Center, Northport, New York 11768, USA
    J Biol Chem 273:1216-22. 1998
  8. ncbi Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease
    J Safranek
    Departments of Surgery, Faculty of Medicine in Pilsen, Charles University in Prague, University Hospital in Pilsen, Czech Republic
    Anticancer Res 29:2513-7. 2009
  9. ncbi Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions
    S Vatansever
    Istanbul University, Istanbul Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
    Clin Invest Med 32:E293-300. 2009
  10. pmc The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor
    Cecilia A Fernandez
    Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    J Biol Chem 285:41886-95. 2010

Research Grants

  1. PATHOGENESIS OF RADIATION-INDUCED KIDNEY INJURY
    Michael Robbins; Fiscal Year: 2004
  2. The Role of SPARC in Neuroblastoma Angiogenesis
    Susan Cohn; Fiscal Year: 2007
  3. Paolo Mignatti; Fiscal Year: 2014
  4. METALLOPROTEINASE IN HORMONE DEPENDENT BREAST CANCER
    Y Shi; Fiscal Year: 1999
  5. ECM PROTEASES IN INFLAMMATION, FIBROSIS & TUMORIGENESIS
    Gregory Goldberg; Fiscal Year: 2000
  6. TWO STEP INHIBITION OF INVASION AND METASTASIS
    Yves DeClerck; Fiscal Year: 1992
  7. AGING AND ENDOTHELIAL CELL FUNCTION
    May Reed; Fiscal Year: 2009
  8. ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
    Chi Ming Liang; Fiscal Year: 1992
  9. Development of Molecular Pharmacodynamic Assays for Targeted Therapies
    John Todd; Fiscal Year: 2009
  10. Molecular Regulation of TIMP-2 in Neuron Cell Cycle
    DIANE JAWORSKI; Fiscal Year: 2007

Detail Information

Publications230 found, 100 shown here

  1. ncbi mRNA expressions of TIMP-1, -2, and -3 and 92-KD type IV collagenase in early human placenta and decidual membrane as studied by in situ hybridization
    T Hurskainen
    Department of Pathology, University of Oulu, Finland
    J Histochem Cytochem 44:1379-88. 1996
    ....
  2. pmc Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor
    E Toschi
    Laboratory of Virology, Istituto Superiore di Sanita, 00161 Rome, Italy
    Mol Biol Cell 12:2934-46. 2001
    ..This suggests a novel pathway by which Tat can increase KS aggressiveness or induce vasculopathy in the setting of HIV-1 infection...
  3. ncbi E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A)
    Linda Troeberg
    Kennedy Institute of Rheumatology Division, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, Hammersmith, London, W6 8LH UK
    Biochemistry 41:15025-35. 2002
    ..Similar models of interaction may apply to TIMP-4. The latter low-affinity site functions in conjunction with the active site of MMP-2 to generate a tight enzyme-inhibitor complex...
  4. ncbi TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism
    Dong Wan Seo
    National Cancer Institute, Center for Cancer Research, Vascular Biology Faculty and Laboratory of Pathology, Extracellular Matrix Pathology Section, National Institutes of Health, Bethesda, MD 20892, USA
    Cell 114:171-80. 2003
    ..Our findings establish an unexpected, MMP-independent mechanism for TIMP-2 inhibition of endothelial cell proliferation in vitro and reveal an important component of the antiangiogenic effect of TIMP2 in vivo...
  5. ncbi Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes
    Yifeng Zhou
    Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Carcinogenesis 25:399-404. 2004
    ..These findings suggest that the presence of the variant allele in the promoter of MMP2 or TIMP2 may be a protective factor for the development of breast cancer...
  6. ncbi Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart
    Stephane Heymans
    CARIM, University Hospital Maastricht, Maastricht, The Netherlands
    Circulation 112:1136-44. 2005
    ..Whether their expression is related to interstitial fibrosis or LV dysfunction in patients with chronic pressure overload-induced LV hypertrophy, however, is unknown...
  7. ncbi Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP)
    S Zucker
    Department of Medicine, Department of Veterans Affairs Medical Center, Northport, New York 11768, USA
    J Biol Chem 273:1216-22. 1998
    ..MT1-MMP complexes in MT1-MMP-transfected COS-1 cell membrane extracts. TIMP-2 receptors were also identified on concanavalin A-treated human umbilical vein endothelial cells; inhibition of TIMP-2 binding with CT-1746 was demonstrated...
  8. ncbi Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease
    J Safranek
    Departments of Surgery, Faculty of Medicine in Pilsen, Charles University in Prague, University Hospital in Pilsen, Czech Republic
    Anticancer Res 29:2513-7. 2009
    ....
  9. ncbi Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions
    S Vatansever
    Istanbul University, Istanbul Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
    Clin Invest Med 32:E293-300. 2009
    ..To investigate diagnostic values of pleural fluid matrix metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitors of metalloproteinase-1 (TIMP-1) and TIMP-2 measurements in tuberculous pleurisy(TP) and malignat pleurisy (MP)...
  10. pmc The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor
    Cecilia A Fernandez
    Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    J Biol Chem 285:41886-95. 2010
    ....
  11. pmc Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers
    N Theret
    Detoxication and Tissue Repair Unit, INSERM U456, Universite de Rennes I, France
    Am J Pathol 153:945-54. 1998
    ....
  12. doi Human chorionic gonadotropin stimulates matrix metalloproteinases-2 and -9 in cytotrophoblastic cells and decreases tissue inhibitor of metalloproteinases-1, -2, and -3 in decidualized endometrial stromal cells
    Herbert Fluhr
    Department of Obstetrics and Gynecology, University of Greifswald, Greifswald, Germany
    Fertil Steril 90:1390-5. 2008
    ..To investigate the influence of hCG on trophoblastic matrix metalloproteinases (MMPs) -2 and -9 as well as endometrial tissue inhibitor of metalloproteinases (TIMPs) -1, -2, and -3...
  13. ncbi Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways
    Ting Wang
    Department of Biochemistry, School of Dentistry, Aichi Gakuin University, 464 8650, Nagoya, Japan
    Biochem Biophys Res Commun 296:201-5. 2002
    ..Furthermore, TIMP-2 promoted the formation of a complex between Ras-GTP and phosphoinositide 3-kinase...
  14. ncbi Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression
    A O'Grady
    Department of Histopathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland
    Histopathology 51:793-804. 2007
    ....
  15. doi Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents
    Vanessa A Belo
    Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 13081 970 Campinas, SP, Brazil
    Clin Biochem 42:984-90. 2009
    ....
  16. doi TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles
    Hanne Offenberg
    Department of Veterinary Pathobiology, Section of Biomedicine, Faculty of Life Sciences, University of Copenhagen, DK 1870 Frederiksberg C, Denmark
    Mol Oncol 2:233-40. 2008
    ..These insights add to the complex picture emerging about the regulation of TIMPs in colorectal cancer...
  17. doi mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor
    Carlos Alberto Scrideli
    Department of Pediatrics, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    Leuk Res 34:32-7. 2010
    ..04) and multivariable analysis (P=0.01). Our data address new information in the complex interaction of the migration/adhesion genes and childhood ALL...
  18. doi Expression of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinase-1 (TIMP-1, TIMP-2 and TIMP-3) in women with uterine prolapse but without urinary incontinence
    Ching Chung Liang
    Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taiwan, ROC
    Eur J Obstet Gynecol Reprod Biol 153:94-8. 2010
    ....
  19. doi 17β-estradiol reduces expression of MMP-1, -3, and -13 in human primary articular chondrocytes from female patients cultured in a three dimensional alginate system
    Horst Claassen
    Institute of Anatomy and Cell Biology, Martin Luther University of Halle Wittenberg, Große Steinstraße 52, 06097, Halle Saale, Germany
    Cell Tissue Res 342:283-93. 2010
    ..Downregulation of TIMP-2 by 17β-estradiol in male patients would not be articular cartilage protective...
  20. pmc Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure
    Jyotica Batra
    Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 32224, USA
    J Biol Chem 287:15935-46. 2012
    ..This structural information may ultimately assist in the design of more selective TIMP-based inhibitors tailored for specificity toward individual members of the stromelysin family, with potential therapeutic applications...
  21. ncbi Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI
    Nicola Fiotti
    Department of Clinical, Morphological and Technological Sciences, Internal Medicine Unit University of Trieste, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy
    Int J Cardiol 127:350-7. 2008
    ....
  22. doi Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas
    Xiaojun Zhang
    Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, Tokyo 142 8555, Japan
    Histopathology 55:250-60. 2009
    ..Our aim was to analyse the mRNA and protein expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 in the epithelium and stroma of pleomorphic adenoma and to evaluate their roles...
  23. ncbi Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution
    A Tuuttila
    Department of Medical Biochemistry and Biophysics Division of Matrix Biology, Karolinska Institutet, Stockholm, S 171 77, Sweden
    J Mol Biol 284:1133-40. 1998
    ....
  24. ncbi Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation
    C M Overall
    Department of Oral Biological and Medical Sciences and the Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
    J Biol Chem 275:39497-506. 2000
    ..Hence, the ectodomain of the remnant 44-kDa form of MT1-MMP appears to play little if any role in the activation of gelatinase A favoring the hypothesis that it accumulates on the cell surface as an inactive, stable degradation product...
  25. ncbi Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy
    Muzahir H Tayebjee
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Diabetes Care 27:2049-51. 2004
  26. ncbi Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent
    Valerie Gouyer
    Unité INSERM 560, Place de Verdun, Lille, France
    Cancer 103:1676-84. 2005
    ..In this study, mRNA expression levels of MMP-1, MMP-9, TIMP-1, and TIMP-2 were evaluated in patients with resected NSCLC, and their associations with disease progression and prognosis were determined...
  27. ncbi Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis
    Ursula Hoffmann
    First Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany
    Scand J Infect Dis 38:867-72. 2006
    ..14-17.6, p = 0.014). Our results indicate that MMP-9, TIMP-2 and TIMP-1 are elevated in severe sepsis. Furthermore, TIMP-1 may serve as a useful laboratory marker to predict the clinical outcome of patients presenting with severe sepsis...
  28. ncbi Gelatinases and their tissue inhibitors during human ovulation: increased expression of tissue inhibitor of matrix metalloproteinase-1
    A K Lind
    Department of Obstetrics and Gynecology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Mol Hum Reprod 12:725-36. 2006
    ..The increased expression of TIMP-1 may reflect a specific temporal inhibition of collagenolysis and thereby a time-dependent regulation of ECM breakdown in areas surrounding the apex of the follicle...
  29. ncbi Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism
    Silvia D'Alessio
    Department of Cardiothoracic Surgery, New York University School of Medicine, NYU Medical Center, 550 First Avenue, New York, NY 10016, USA
    J Biol Chem 283:87-99. 2008
    ..These findings illustrate a novel role for MT1-MMP-TIMP-2 interaction, which controls cell functions by a mechanism independent of extracellular matrix degradation...
  30. doi Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry
    Dominique Trudel
    Department of Pathology, Centre Hospitalier Universitaire de Québec CHUQ and Université Laval, Quebec, Canada G1K 7P4
    Hum Pathol 39:731-9. 2008
    ..0001). This study suggests that MMP14 is involved mostly in Pca implantation and that MMP2 and TIMP2 expression by reactive stromal cells might be used as predictors of DFS in T3N0-2M0 Pca...
  31. doi Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension
    Ana C T Palei
    Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 13081 970, Campinas, SP, Brazil
    Clin Biochem 41:875-80. 2008
    ....
  32. ncbi Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues
    W G Stetler-Stevenson
    Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892
    J Biol Chem 265:13933-8. 1990
    ..This is in contrast to the elevated timp-1 transcript levels seen in these tumor samples. Thus, timp-2 mRNA transcript levels are differentially regulated from timp-1 levels in vivo as well as in cell culture...
  33. ncbi Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2)
    Y A De Clerck
    Division of Hematology Oncology, Childrens Hospital Los Angeles, CA 90054 0700
    Gene 139:185-91. 1994
    ..A comparison with the promoter of murine timp-1 revealed several differences consistent with the fact that timp-1 and timp-2 are differentially regulated...
  34. ncbi Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease
    K Hirano
    Dept of Pulmonary Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Eur Respir J 18:748-52. 2001
    ....
  35. ncbi Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium
    Hye Won Chung
    Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, Korea
    Fertil Steril 78:787-95. 2002
    ....
  36. ncbi Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor
    Cecilia A Fernandez
    Laboratory of Surgical Research, Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    J Biol Chem 278:40989-95. 2003
    ..In addition, we report, for the first time, the discovery of Loop 6 as a novel and potent inhibitor of angiogenesis...
  37. ncbi Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue
    B Brehmer
    Clinic of Urology, University Clinic Aachen, Germany
    Prostate Cancer Prostatic Dis 6:217-22. 2003
    ..The observed imbalance of MMP and TIMP is mainly caused by a loss of TIMP-1. Furthermore, palpable tumours demonstrated significantly more MMP-2 and significantly less MMP-9 expression than nonpalpable tumours...
  38. ncbi Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms
    Dietmar Krex
    Department of Neurosurgery, University Hospital Carl Gustav Carus, University of Technology, Dresden, Germany
    Stroke 34:2817-21. 2003
    ..Their activity is controlled predominantly by tissue inhibitors of metalloproteinases (TIMPs). To investigate the possible impact of genetic variants within the genes encoding TIMP-1, -2, and -3, we conducted this case-control study...
  39. ncbi Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis
    Hidayatullah G Munshi
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Biol Chem 279:39042-50. 2004
    ....
  40. ncbi TIMP-2: an endogenous inhibitor of angiogenesis
    William G Stetler-Stevenson
    Cell and Cancer Biology Branch, Vascular Biology Faculty, CCR, NCI, NIH, Bldg 10, Room 2A33, MSC 1500, 10 Center Dr, Bethesda, MD 20892 1500, USA
    Trends Mol Med 11:97-103. 2005
    ..These new findings are integrated in a comprehensive model of TIMP-2 function in tissue homeostasis...
  41. ncbi Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension
    Muzahir H Tayebjee
    Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK
    Am J Hypertens 18:325-9. 2005
    ....
  42. ncbi Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment
    C Avolio
    Department of Medical and Occupational Sciences, University of Foggia, Foggia, Italy
    Mult Scler 11:441-6. 2005
    ..85; P < 0.05) of the numbers of MRI Gd-TD active lesions. These data confirm that serum MMP-9/TMIP-1 ratio may be viewed as a reliable marker and may be predictive of MRI activity in RR MS...
  43. ncbi Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma
    Zi Bin Gao
    Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, PR China
    Int J Mol Med 16:599-603. 2005
    ..Therefore, MMP-2 and TIMP-2 may play important roles in the invasion and metastasis of OSCC...
  44. ncbi The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer
    Pornchai O-Charoenrat
    Department of Head and Neck Surgery, Faculty of Medicine, Siriraj Hospital Medical School, Mahidol University, 2 Prannok Road, Bangkok 10700, Thailand
    Oral Oncol 42:257-67. 2006
    ..These findings suggest that the genetic polymorphisms in the promoters of MMP2 and TIMP2 may be associated with the development and aggressiveness of HNSCC...
  45. pmc Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells
    Dong Wan Seo
    Cell and Cancer Biology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892 1500, USA
    J Biol Chem 281:3711-21. 2006
    ....
  46. ncbi Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course
    Henni Ruokolainen
    Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland
    Mod Pathol 19:208-17. 2006
    ....
  47. pmc TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118
    J Oh
    Laboratory of Cellular Oncology, Korea University Graduate School of Medicine, Ansan, Gyeonggi Do, Korea
    Oncogene 25:4230-4. 2006
    ..Therefore, TIMP-2-mediated inhibition of Src kinase activity leads to the signaling switch from Rac1 to Rap1, thereby leading to enhanced RECK expression...
  48. ncbi Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease
    Hyun Seung Kang
    Department of Neurosurgery, Konkuk University Hospital, Seoul, Korea
    Neurosurgery 58:1074-80; discussion 1074-80. 2006
    ..2-p26 and 17q25, respectively, which are the locations of familial moyamoya disease (FMMD) genes. We investigated single nucleotide polymorphisms of the TIMP2 and TIMP4 genes in FMMD patients to determine genetic predispositions...
  49. pmc Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer
    F J G M Kubben
    Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
    Br J Cancer 95:744-51. 2006
    ..We conclude that MMP-related SNPs, especially MMP-7(-181A>G) and TIMP-2(303C>T), may be helpful in identifying gastric cancer patients with a poor clinical outcome...
  50. ncbi Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer
    Chun Ying Wu
    Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
    Eur J Cancer 43:799-808. 2007
    ..We aim to elucidate the role of MMP-2 and TIMP-2 in clinicopathological manifestations of gastric cancer...
  51. pmc Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors
    S M Pulukuri
    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL 61656, USA
    Oncogene 26:5229-37. 2007
    ..These results suggest that the downregulation of the TIMP-2 gene is associated with promoter methylation and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease...
  52. ncbi Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans
    Eleftherios Vairaktaris
    Department of Maxillofacial Surgery, University of Athens Medical School, 11521 Athens, Greece
    Oncol Rep 17:963-8. 2007
    ..These results indicate that this polymorphism could serve as a genetic marker for the susceptibility of cancer in the oral cavity...
  53. ncbi Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population
    L Yang
    Key Laboratory of Reproductive Medicine, Department of Pharmacology, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, Jiangsu Province, China
    Eur J Surg Oncol 34:636-41. 2008
    ..To examine the effect of the TIMP-2 G-418C polymorphism on gastric cancer risk...
  54. ncbi [Association of SNPs in the promoter of MMP-2 and TIMP-2 genes with epithelial ovarian cancer]
    Xiu Lan Li
    The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
    Yi Chuan 30:455-62. 2008
    ..The TIMP-2 G-418C SNP may be associated with the risk of different histological subtypes of epithelial ovarian cancer...
  55. ncbi Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer
    H Alakus
    Department of Visceral and Vascular Surgery, University of Cologne, Cologne, Germany
    Histol Histopathol 23:917-23. 2008
    ....
  56. pmc Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells
    Nor Eddine Sounni
    Cancer Research Center, Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Int J Cancer 126:1067-78. 2010
    ..The TIMP-2-induced stimulation of ERK signaling in cancer cells explains the direct, as opposed to the inverse, association of TIMP-2 expression with poor prognosis in cancer...
  57. doi Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer
    Yu Chiao Yi
    Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan
    Clin Chim Acta 409:127-31. 2009
    ..We investigated the association of TIMP-1 and TIMP-2 gene polymorphism with risk of endometrial cancer...
  58. doi TIMP-2 gene polymorphism is associated with intracerebral hemorrhage
    Bjoern Reuter
    Department of Neurology, Universitatsklinikum Mannheim, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    Cerebrovasc Dis 28:558-63. 2009
    ..TIMP-2 is an important endogenous inhibitor of MMP-2. Alterations in the TIMP-2 gene expression may contribute to the incidence of ischemic stroke and intracerebral hemorrhage...
  59. doi Association of a functional polymorphism in the MMP-3 gene with Moyamoya Disease in the Chinese Han population
    Hao Li
    Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, PR China
    Cerebrovasc Dis 30:618-25. 2010
    ..The study was designed to examine the association of single nucleotide polymorphisms in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP) genes with MMD occurrence...
  60. doi Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer
    Kyung Sook Park
    Department of Biology, Sungshin Women s University, Seoul, Korea
    J Gastroenterol Hepatol 26:391-7. 2011
    ..Genetic variations and the expression profile of matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) are involved in the invasion and metastasis of colorectal cancer...
  61. doi Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients
    Magdalena Groblewska
    Department of Biochemical Diagnostics, Medical University, Białystok, Poland
    Folia Histochem Cytobiol 48:564-71. 2010
    ..Our findings suggest clinical usefulness of TIMP-2 as a biomarker in the diagnosis of CRC, especially in combination with CEA. However, further investigation is necessary...
  62. pmc Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1))
    Harinath Bahudhanapati
    Department of Basic Science, Charles E Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida 33431, USA
    J Biol Chem 286:31761-70. 2011
    ..This study suggests that phage display and selection with other MMPs may be an effective method for discovering tissue inhibitor of metalloproteinase variants that discriminate between specified MMPs as targets...
  63. pmc NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats
    Jiandong Yang
    Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi an, China
    PLoS ONE 6:e27710. 2011
    ..In conclusion, the present findings indicate that the modulation of NDRG2 is a promising strategy for the treatment of liver fibrosis...
  64. doi Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India
    Priyanka Srivastava
    Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
    Arch Med Res 43:117-24. 2012
    ..We sought to determine whether genetic polymorphisms in MMP2 and TIMP2 polymorphisms may be associated with varying risk of prostate cancer (PCa) in men in North India...
  65. ncbi HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes
    R M Lafrenie
    Laboratories of Developmental Biology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD, USA
    J Immunol 157:974-7. 1996
    ....
  66. pmc Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor
    C Fernandez-Catalan
    Max Planck Institut fur Biochemie, Am Klopferspitz 18a, D 82152 Martinsried Planegg, Germany
    EMBO J 17:5238-48. 1998
    ..The lower affinity of TIMP-1 for MT1-MMP compared with TIMP-2 might be explained by a reduced number of favourable interactions...
  67. ncbi MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival
    Lydia Nakopoulou
    Department of Pathology, Medical School, The National and Kapodistrian University of Athens, Athens, Greece
    Breast Cancer Res Treat 77:145-55. 2003
    ..The inverse correlation between MMP-2 and both Ki-67 and p53 can be explained by the potential inhibition of MMP-2 by TIMP-2. These results suggest the necessity of further investigation...
  68. ncbi Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy
    Arpad von Moers
    Department of Neuropediatrics, Charite, University Medical Center Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
    Acta Neuropathol 109:285-93. 2005
    ..TIMP-1 should be investigated further as a promising target for pharmacological intervention to prevent muscle fibrosis in DMD...
  69. ncbi Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2
    Jean Luc Brun
    Departments of Gynecology, AP HP, Hopital Tenon, 4 rue de la Chine, F 75571 Paris Cedex, France
    Int J Oncol 33:1239-46. 2008
    ..In conclusion, our results support the differential expression in MMPs and TIMPs of ovarian tumors according to serous or mucinous histology...
  70. ncbi Differential growth regulation in human melanoma cell lines by TIMP-1 and TIMP-2
    T Hoashi
    Department of Dermatology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Biochem Biophys Res Commun 288:371-9. 2001
    ..The growth of the primary melanoma cell lines was stimulated by TIMP-1 and inhibited by TIMP-2. In contrast, the growth of the visceral metastatic melanoma cell line was stimulated by TIMP-2...
  71. ncbi Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state
    Konstantinos Aznaouridis
    Atherosclerosis 195:212-5. 2007
  72. ncbi Functional role of matrix metalloproteinases in ovarian tumor cell plasticity
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Obstet Gynecol 190:899-909. 2004
    ..We also investigated the clinical relevance of matrix metalloproteinase-2 and -9 and membrane type 1-matrix metalloproteinase in human ovarian cancers with evidence of tumor cell-lined vasculature...
  73. ncbi Matrix metalloproteinase-9 and tensile strength of fetal membranes in uncomplicated labor
    K Uchide
    Department of Obstetrics and Gynecology, School of Medicine, School of Medicine, Kanazawa University, 13 1, Kanazawa, 920 8641, Takara machi, Japan
    Obstet Gynecol 95:851-5. 2000
    ..To analyze the relation between tensile strength and levels of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2 at a number of sites in human fetal membranes...
  74. ncbi [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass]
    Jarosław Paśnik
    Klinika Pediatrii i Immunologii Wieku Rozwojowego Uniwersytetu Medycznego w Łodzi
    Przegl Lek 66:359-64. 2009
    ..We demonstrated the link between CPB duration and the MMP-9 concentration. Future studies will determine whether inhibition of MMPs activity diminishes morbidity in children after cardiac surgery...
  75. doi Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers
    Saher B Shaker
    Department of Cardiology and Respiratory Medicine, Hvidovre University Hospital, Copenhagen, Denmark
    Clin Respir J 2:17-25. 2008
    ..Inflammation is an important constituent of the pathology of chronic obstructive pulmonary disease (COPD), leading to alveolar destruction and airway remodelling...
  76. pmc Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer
    Tae Dong Kim
    Department of Surgery, College of Medicine, Chungnam National University and Hospital, Daejeon, 301 721, Korea
    BMC Cancer 6:211. 2006
    ..We designed this study to determine any differences in the expression of MMP-2, MMP-9 and uPA system between colon and rectal cancer tissues...
  77. ncbi Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2
    P T Nygårdas
    Department of Biochemistry and Pharmacy, Abo Akademi University, Turku, Finland
    Scand J Immunol 60:372-81. 2004
    ..TIMPs might be candidates for novel treatment regimens in CNS autoimmune disorders, such as multiple sclerosis...
  78. ncbi Effects of tissue inhibitor of metalloproteinase 2 deficiency on aneurysm formation
    Wanfen Xiong
    Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198 7690, USA
    J Vasc Surg 44:1061-6. 2006
    ..At higher concentrations, TIMP-2 becomes an inhibitor of MMP-2. Thus, TIMP-2 could both augment and inhibit matrix degradation. This study was undertaken to define the net effect of TIMP-2 on matrix destruction and aneurysm formation...
  79. ncbi The expression of tissue inhibitor of metalloproteinase 2 (TIMP-2) is required for normal development of zebrafish embryos
    Jinsong Zhang
    Department of Anatomy and Cell Biology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    Dev Genes Evol 213:382-9. 2003
    ..This is in contrast to murine knockout studies that indicate that TIMP-2 does not have a major role in mouse embryogenesis...
  80. ncbi TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface
    Stanley Zucker
    Department of Research, Veterans Affairs Medical Center, Northport, NY 11768, USA
    Exp Cell Res 293:164-74. 2004
    ..In conclusion, these studies demonstrate that TIMP-2 is released from cells primarily as an intact functional molecule following binding to MT1-MMP on the cell surface...
  81. ncbi Basement membrane integrity and keratinization in healthy and ulcerated bovine hoof tissue
    Kay A K Hendry
    Hannah Research Institute, Hannah Research Park, Ayr, KA6 5HL, UK
    J Dairy Res 70:19-27. 2003
    ..Tissue inhibitor of metalloproteinase 2 (TIMP 2) was detected by ELISA in healthy tissue...
  82. pmc Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2)
    Marie Kveiborg
    Department of Biomedical Sciences and Biotech Research and Innovation Centre, University of Copenhagen, Denmark
    Biochem J 430:79-86. 2010
    ..Taken together, our findings support the idea that a distinctive ADAM12 inhibitor with future therapeutic potential can be designed...
  83. pmc Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice
    Diane M Jaworski
    Department of Anatomy and Neurobiology, University of Vermont College of Medicine, 149 Beaumont Avenue, HSRF 418, Burlington, Vermont 05405, USA
    Endocrinology 152:1300-13. 2011
    ....
  84. ncbi Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression
    U B Hofmann
    Department of Pathology and Surgery, University Hospital, Nijmegen, The Netherlands
    J Invest Dermatol 115:625-32. 2000
    ..These findings strongly suggest that co-ordinated expression of both factors may be required for melanoma cell invasion and metastasis formation...
  85. pmc Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients
    Bozena Dziankowska-Bartkowiak
    Division of Immunodermatology, Medical University of Lodz, Poland
    Mediators Inflamm 2005:144-9. 2005
    ..Evaluation of endostatin and TIMP2 serum levels seems to be one of the noninvasive, helpful examinations of heart involvement in the course of systemic sclerosis...
  86. pmc Differential effect of 17-beta-estradiol on smooth muscle cell and aortic explant MMP2
    Derek T Woodrum
    Department of Surgery, Section of Vascular Surgery, Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan 48109 0329, USA
    J Surg Res 155:48-53. 2009
    ..The present investigation tested the hypothesis that intrinsic gender-related differences exist in rat aortic smooth muscle cell matrix metalloproteinase 2 (MMP2)...
  87. ncbi Amniochorion gelatinase-gelatinase inhibitor imbalance in vitro: a possible infectious pathway to rupture
    S J Fortunato
    Maternal Fetal Group and Perinatal Research Center of the Women s Health Research and Education Foundation and Aquinas College, Nashville, Tennessee 37203, USA
    Obstet Gynecol 95:240-4. 2000
    ..To estimate the effect of lipopolysaccharide on gelatinases and tissue inhibitors of matrix metalloproteinase 2 (gelatinase inhibitor) balance in human fetal membranes...
  88. doi Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling
    Margherita Branca
    Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanita, Rome, Italy
    Int J Gynecol Pathol 27:265-73. 2008
    ..However, testing the performance of this marker combination in a screening setting necessitates their analysis in cytological samples...
  89. pmc Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells
    Yu Qing Lan
    Department of Ophthalmology, The Second Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, China
    Mol Vis 15:1977-87. 2009
    ..This experiment was designed to test whether reduction of inhibitor of nuclear factor kappa B alpha (IkappaBalpha) levels could enhance MMP-2 expression in human ciliary muscle (HCM) cells in vitro...
  90. pmc Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism
    Gentian Lluri
    Department of Anatomy and Neurobiology, University of Vermont College of Medicine, Burlington, Vermont 05405, USA
    J Neurobiol 66:1365-77. 2006
    ..Given that fast-twitch fibers are lost in muscular dystrophies and age-related sarcopenia, if TIMP-2 regulates mechanotransduction in an MMP-independent manner it opens new potential therapeutic avenues...
  91. ncbi Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase
    Jian Cao
    Department of Medicine, School of Medicine, State University of New York at Stony Brook, Stony Brook, New York 11794 5200, USA
    J Biol Chem 280:10974-80. 2005
    ..In conclusion, we report the novel observation that furin can directly cleave the RXXR amino acid sequence in the propeptide domain of proMMP-2 leading to inactivation of the enzyme...
  92. pmc Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients
    Neel R Sodha
    Division of Cardiothoracic Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Arch Surg 143:463-70. 2008
    ..Antiangiogenic protein expression is increased in skeletal muscle in the setting of diabetes...
  93. pmc Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3
    Alpna Tyagi
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Denver, CO 80262, USA
    Cancer Prev Res (Phila) 2:74-83. 2009
    ....
  94. doi Cyclosporine A inhibits the expression of membrane type-I matrix metalloproteinase in gingiva
    H C Chiu
    Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, China
    J Periodontal Res 44:338-47. 2009
    ..Therefore, the expressions of membrane type-I MMP and TIMP-2, as well as MMP-2, in gingivae upon treatment with cyclosporine A were examined in vivo and in vitro...
  95. ncbi Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase- plasminogen activator
    Yuan Wei Shih
    Department of Biological Science and Technology, and Graduate Institute of Biomedical Science, Chung Hwa Universit of Medical Technology, Tainan, Taiwan
    Hepatol Res 39:998-1009. 2009
    ....
  96. ncbi Kinetic analysis of the mechanism of interaction of full-length TIMP-2 and gelatinase A: evidence for the existence of a low-affinity intermediate
    M Hutton
    School of Biological Sciences, University of East Anglia, Norwich, UK
    Biochemistry 37:10094-8. 1998
    ..This gives a value for the overall dissociation constant of approximately 0.6 fM...
  97. ncbi Limited processing of pro-matrix metalloprotease-2 (gelatinase A) overexpressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1
    Michael J Wilson
    Minneapolis VA Medical Center, and Department of Laboratory Medicine and Pathology, and Minnesoata Cancer Center, University of Minnesota, Minneapolis, USA
    J Androl 25:274-85. 2004
    ..The molecular basis for the low level of processing of pro-MMP-2 by PC-3 cells may be due to an overabundance of TIMP-2 and/or a low level of cell surface active MT1-MMP...
  98. pmc Activities of matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in idiopathic hemotympanum and otitis media with effusion
    Sung K Moon
    Gonda Department of Cell and Molecular Biology, House Ear Institute, Los Angeles, CA, USA
    Acta Otolaryngol 128:144-50. 2008
    ..Further studies are necessary for elucidating its correlation with the sequelae of otitis media with effusion (OME) and idiopathic hemotympanum...
  99. ncbi Matrix metalloproteinases (MMPs) safeguard osteoblasts from apoptosis during transdifferentiation into osteocytes: MT1-MMP maintains osteocyte viability
    M A Karsdal
    Nordic Bioscience A S, CCBR, Herlev Ballerup, DK 2730 Herlev, Denmark
    DNA Cell Biol 23:155-65. 2004
    ..Thus, the interrelationship of MMPs and TGF-beta may play an important role in bone formation and maintenance...
  100. ncbi ATP stimulates MMP-2 release from human aortic smooth muscle cells via JNK signaling pathway
    William P Robinson
    Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7228, USA
    Am J Physiol Heart Circ Physiol 290:H1988-96. 2006
    ..Nucleotides are thus novel stimulants of MMP-2 release from HASMCs and may provide a mechanistic link between physiochemical stress in the aorta and aneurysms, especially in the context of inflammation...
  101. ncbi Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, University of Oslo, Oslo, Norway
    Clin Cancer Res 10:7335-46. 2004
    ....

Research Grants32

  1. PATHOGENESIS OF RADIATION-INDUCED KIDNEY INJURY
    Michael Robbins; Fiscal Year: 2004
    ..These studies offer the promise of developing rational therapeutic strategies directed at reducing the severity of this dose-limiting morbidity in human beings. ..
  2. The Role of SPARC in Neuroblastoma Angiogenesis
    Susan Cohn; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  3. Paolo Mignatti; Fiscal Year: 2014
    ..The knowledge derived from our study will be of fundamental importance for designing novel pharmacological agents to block tumor progression. ..
  4. METALLOPROTEINASE IN HORMONE DEPENDENT BREAST CANCER
    Y Shi; Fiscal Year: 1999
    ....
  5. ECM PROTEASES IN INFLAMMATION, FIBROSIS & TUMORIGENESIS
    Gregory Goldberg; Fiscal Year: 2000
    ....
  6. TWO STEP INHIBITION OF INVASION AND METASTASIS
    Yves DeClerck; Fiscal Year: 1992
    ..They will represent the combined effort of an investigator (PI) with expertise in cell biology of metastasis and metalloproteinase inhibitors and a protein chemist (co-PI) who has studied snake venom proteins for a number of years...
  7. AGING AND ENDOTHELIAL CELL FUNCTION
    May Reed; Fiscal Year: 2009
    ..The elucidation of mechanisms that regulate MMP activity in aged cells and tissues will assist the development of therapies to improve wound repair and revascularization of ischemic organs. ..
  8. ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
    Chi Ming Liang; Fiscal Year: 1992
    ..These molecules will be tested for potential therapeutic uses in wound healing, angiogenesis, treatment of rheumatoid arthritis and prevention of cancer metastasis...
  9. Development of Molecular Pharmacodynamic Assays for Targeted Therapies
    John Todd; Fiscal Year: 2009
    ..We will carry out preliminary validation of these assays and demonstrate feasibility of these assays for measuring the target analytes in human tissues. ..
  10. Molecular Regulation of TIMP-2 in Neuron Cell Cycle
    DIANE JAWORSKI; Fiscal Year: 2007
    ..abstract_text> ..
  11. Structure-based Drug Design for Smallpox Therapy
    Alex Strongin; Fiscal Year: 2008
    ..When appropriate benchmarks are met, the drug candidates will be delivered to the government for continued testing and refinement involving the variola virus. [unreadable] [unreadable]..
  12. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2009
    ..The results of these experiments have a very high probability of providing an effective means to regulate the MT1-MMP function in the setting of the disease. ..
  13. ENDOTHELIAL BARRIER FUNCTION IN PREECLAMPSIA
    Yuping Wang; Fiscal Year: 2010
    ..The influence of CLP on placental sFlt-1 will be studied. Results obtained from the proposed work should enhance current knowledge of the role of the placenta and EC dysfunction in the pathogenesis of PE. ..
  14. REGULATION OF LUTEAL FUNCTION
    Geula Gibori; Fiscal Year: 2009
    ....
  15. PLACENTAL FUNCTION IN PREECLAMPSIA
    Yuping Wang; Fiscal Year: 2009
    ..Results obtained from the proposed work should enhance our knowledge and establish a direct link of placental TC activity and EC dysfunction in PE. ..
  16. Hepatic Stellate Cell Derived MMP9 in Liver Fibrogenesis
    Yuan Ping Han; Fiscal Year: 2008
    ..Lastly, knock-out and knock-in methods will be used to test the roles of IL-1 signaling and MMP-9 expression in early and late liver fibrogenesis in vivo. ..
  17. ACT,a pathophysiological inhibitor of MMP-9 activation
    Yuan Ping Han; Fiscal Year: 2008
    ..Understanding the function, structure and regulation of the inhibitor can provide information for future application in developing of therapy for abnormal wounds and cancer metastasis. ..
  18. Vascular Biology of Tissue Factor
    Wolfram Ruf; Fiscal Year: 2008
    ..These studies have, and will continue to produce original data and advanced knowledge of the TF driven thrombotic and inflammatory diseases and new routes to reduce the impact of these diseases. ..
  19. MMP-2 in Neonatal Hypoxic Pulmonary Vascular Remodeling
    Namasivayam Ambalavanan; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  20. Association of 7q22..1 gene VGF with obesity & leanness
    John Martignetti; Fiscal Year: 2008
    ..These physiologically linked, target-tissue genes may themselves play a functional role in obesity resistance or susceptibility, and thus become excellent candidates for future investigation. ..
  21. C-Reactive Protein in Extremely Low Birth Weight Neonates
    Namasivayam Ambalavanan; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  22. Hydroxamate-based therapy to target T cell homing in IDDM
    Alex Strongin; Fiscal Year: 2007
    ..We strongly believe that the results of [unreadable] our experimental program will lead to the development of new and effective anti-diabetic therapies for IDDM patients. [unreadable] [unreadable] [unreadable]..
  23. Regulation of Signaling in Osteoclast Bone Resorption
    Meenakshi Chellaiah; Fiscal Year: 2007
    ..abstract_text> ..
  24. GENETIC DISSECTION OF A BONE DYSPLASIA/CANCER SYNDROME
    John Martignetti; Fiscal Year: 2002
    ....
  25. FUNCTION OF THE DECIDUAL TISSUE
    Geula Gibori; Fiscal Year: 2007
    ..We will also test the hypothesis that fetal death in 5alphaReductase type 1 null mice is due to the inhibition of IL-11 signaling in the decidua by high levels of estradiol. ..
  26. VASCULAR BIOLOGY IN CANCER
    Thomas Edgington; Fiscal Year: 2006
    ..Weekly seminars and review of data are conducted by each of the faculty members with their group. M.D., Ph.D. and M.D./Ph.D. candidates are recruited and prepared for an independent investigative career. ..
  27. Develop Effective Inhibitors of Anthrax Lethal Factor
    Alex Strongin; Fiscal Year: 2006
    ..We are confident that the resulting LF antagonist(s) will efficiently and safely provide the therapy that is so urgently required. ..
  28. Novel dendritic cell therapy for human cancers
    Selvarangan Ponnazhagan; Fiscal Year: 2005
    ....
  29. INHIBITION OF CELL-MEDIATED PROMMP-2 ACTIVATION IN ORAL CANCER
    Xiaoping Xu; Fiscal Year: 2008
    ..This research project will test new approaches to inhibit MMPs. The goal is to develop MMP inhibitors for treatment of oral cancer. [unreadable] [unreadable] [unreadable]..
  30. CYTOKINES CONVERT EPITHELIAL PRECURSORS TO NEPHRONS
    Jonathan M Barasch; Fiscal Year: 2010
    ..We apply the basic ideas and tools of cell biologyto define the course of polarization and establish a fluorescent polarity mouse to evaluate the entire transition form mesenchyme to epithelia. ..
  31. Arterial 5-HT Transporter Function
    Stephanie Watts; Fiscal Year: 2009
    ..abstract_text> ..
  32. Targeting the PEX Domain of MT1-MMP: Novel Cancer Therapy
    Jian Cao; Fiscal Year: 2010
    ..I propose that the current project will help us to better understand cancer progression and lead to the development of novel basic tools for treatment of early stage cancer. ..